Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sheraz Mian headshot

Q4 Earnings Scorecard and Analyst Reports for Sony, Mondelez & Twilio

We have provided a real-time update on the Q4 earnings season, in addition to featuring new research reports on 16 major stocks in today's Research Daily.

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.

Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance

Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.

The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express

The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express

Sheraz Mian headshot

Top Research Reports for Facebook, Novo Nordisk & SAP

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Novo Nordisk (NVO), and SAP SE (SAP).

Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?

Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.

Mark Vickery headshot

Top Analyst Reports for Amazon, Thermo Fisher & Eli Lilly

Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Thermo Fisher Scientific (TMO), and Eli Lilly (LLY).

Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand

Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.

AstraZeneca (AZN) Farxiga Gets Priority Tag for Kidney Disease

If approved for CKD, AstraZeneca's (AZN) Farxiga will be the first SGLT2 inhibitor approved to treat patients with CKD, with and without type II diabetes.

Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance

Pfizer's (PFE) BLA for growth hormone deficiency (GHD) gets accepted by the FDA for standard review. FDA's decision expected in October 2021.

Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU

Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.

Sheraz Mian headshot

Top Analyst Reports for Alphabet, Comcast & Accenture

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Comcast (CMCSA) and Accenture (ACN).

Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU

Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.

Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study

Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.

The Zacks Analyst Blog Highlights: Alibaba, QUALCOMM, Novo Nordisk, Boeing and Delta Air Lines

The Zacks Analyst Blog Highlights: Alibaba, QUALCOMM, Novo Nordisk, Boeing and Delta Air Lines

Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy

Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.

Sheraz Mian headshot

Top Research Reports for Alibaba, QUALCOMM & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), QUALCOMM Incorporated (QCOM) and Novo Nordisk AS (NVO).

FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda

Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.

AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure

AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.

Is Novo Nordisk (NVO) a Suitable Stock for Value Investors?

Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint

Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

The Zacks Analyst Blog Highlights: Facebook, Verizon, Toyota Motor, Novo Nordisk, Applied Materials and General Motors

The Zacks Analyst Blog Highlights: Facebook, Verizon, Toyota Motor, Novo Nordisk, Applied Materials and General Motors

Sheraz Mian headshot

Top Research Reports for Facebook, Verizon & Toyota Motor

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Verizon Communications (VZ) and Toyota Motor (TM).